Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma

• 作 者: TianwenLai;ZhiweiXu;ChaoZhang;ChaoCao;SongminYing;ZhihuaChen;WenLi;BinWu;HuahaoShen;
• 机 构: Respiratory and Critical Care Medicine,Second Affiliated Hospital,Zhejiang University School of Medi
• 出 处: 中华医学会第七次全国高原医学学术会议暨中国病理生理学会第九次全国缺氧和呼吸病理生理学术会议
• 发表日期: 2014年期

　　Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma.In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab as an add-on therapy in patients with persistent uncontrolled allergic asthma, and to (ii) discuss the cost-effectiveness evidence published for omalizumab in this patient population.A comprehensive search for randomized controlled trials (RCTs; ≥52 weeks) was performed, and six studies met our final inclusion criteria (n=2,749).Omalizumab was associated with a significant decrease in the risk of asthma exacerbation compared with conventional therapy, and with significant improvements in quality of life.Omalizumab also allowed patients to completely withdraw from inhaled corticosteroid therapy, and it achieved better results in the Global Evaluation of Treatment Effectiveness than did the standard therapies.Omalizumab did not increase the overall incidence of adverse events.